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• • 
DISCUSSION
• Birth outcomes for members receiving progesterone for 
the prevention of PTB in the MassHealth PCC plan were 
consistent with clinical trial data.6 
• Medication adherence among MassHealth PCC plan 
members was similar to or lower than findings from  
other studies.7,8 
• Bivariate and multivariate analyses did not identify member 
characteristics associated with either birth outcomes or 
medication adherence.
• Differences in cost of care in a prior pregnancy and current 
pregnancy are driven by differences in the estimated cost 
of medical care between gestational ages of delivery.
LIMITATIONS
• A significant percentage of race data was reported as 
unknown. 
• Identification of delivery and clinical comorbidities were 
based upon ICD-9 and ICD-10 medical claims data. It was 
not feasible to investigate all potential risk factors that are 
not routinely recorded in medical claims. 
• The date of progesterone administration used for the  
PDC calculation is assumed to be the date of the paid 
pharmacy claim.
 – Costs of progesterone therapy were based on 
wholesale acquisition cost and medical care costs 
were obtained from literature5
 – The gestational age for prior pregnancy was obtained 
from the PA request and the gestational age of the 
study pregnancy was calculated based on date of 
delivery in claims data 
• Statistical Analysis:
 – Descriptive analyses were conducted to report study 
population characteristics.
 – Bivariate analyses were conducted to evaluate the 
associations between member characteristics and 
medication adherence and birth outcome.
 ° For the birth outcome analysis, the independent 
variables included demographic characteristics, 
clinical comorbidities, and medication adherence
 ° For the medication adherence analysis, the 
independent variables included demographic 
characteristics and clinical comorbidities
 – A multivariate logistic regression model was used 
to quantify the associations between birth outcome 
and the potential predictors, adjusting for age, race, 
number of clinical comorbidities and PDC
 – All analyses were completed using SAS 9.4.
OBJECTIVE
Primary Objective:
• To report medication adherence and birth outcomes 
among members receiving progesterone for the prevention 
of PTB in a state Medicaid program.
Secondary Objectives:
• To evaluate the association between member 
characteristics and medication adherence and birth 
outcomes. 
• To estimate the change in cost of care for study pregnancy 
compared to prior preterm pregnancy.
STUDY DESIGN
• This retrospective cohort study evaluated MassHealth 
Primary Care Clinician (PCC) plan members who had a 
PA request submitted for hydroxyprogesterone caproate 
injection or progesterone vaginal gel for the prevention of 
PTB between January 1, 2011 and March 31, 2015. 
• Data was obtained from medical claims, pharmacy claims, 
eligibility and enrollment records, and PA requests. 
• Members were excluded if MassHealth was the secondary 
payer, there were any breaks in MassHealth coverage, 
progesterone was not indicated for the prevention of PTB, 
the current gestational week was not provided on the PA 
form, or date of delivery was not available in claims data.
METHODS
• Outcomes collected included: 
 – Member (age, race) and prescriber (type, specialty) 
demographics 
 – Clinical comorbidities (nutritional disorders, anemia, 
depression, anxiety, bacteriuria, sexually transmitted 
disease, and substance use disorder), identified through 
ICD-9 and -10 codes
 – Medication adherence (defined as proportion of days 
covered [PDC] ≥0.8)
 – Birth outcomes (term vs. preterm)
• For members who had information regarding their 
prior pregnancy on the PA request, a cost of care 
subanalysis comparing the prior pregnancy and 
study pregnancy was performed.  
 – Medical costs alone were used to calculate cost of prior 
pregnancy, and medical cost plus cost of progesterone 
therapy was used to calculate cost of study pregnancy
RESULTS
CONCLUSIONS
• Timely availability and access to data are important  
for monitoring risk factors and evaluating programs. 
• Medicaid members receiving progesterone for the 
prevention of PTB may benefit from additional care 
management services, including adherence programs.
BACKGROUND
• Preterm birth (PTB), or delivery before 37 weeks of 
gestation, is the leading cause of infant morbidity and 
mortality in the United States, affecting 9.6% of births.1 
• History of PTB and cervical shortening during pregnancy 
are among the strongest risk factors for PTB. Progesterone 
has been shown to reduce PTB rates by one-third among 
women at high risk.2-4
• The Massachusetts Medicaid Program (MassHealth) 
has required prior authorization (PA) for use of 
hydroxyprogesterone caproate injection (Makena®)  
and progesterone vaginal gel (Crinone®) since 2011  
and 2012, respectively.
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Characteristic Members who received progesterone for prevention of PTB N=169a
Age
Mean age, in years (SD) 29.2 (5.2)
16-24 39 (23.1)
25-34 107 (63.3)
35-45 23 (13.6)
Race
Black 30 (17.8)
Non-black 139 (82.2)
White 59 (42.5)
Other 28 (20.1)
Unknown 52 (37.4)
Prescriber type
MD 125 (74.0)
DO 16 (9.4)
NP 14 (8.3)
CNM 14 (8.3)
Prescriber specialty 
OB/GYN 98 (58.0)
MLP 28 (16.6)
OB/GYN, MFM specialty 26 (15.4)
Family Medicine 17 (10.0)
Term deliveryb
Term 105 (62.1)
Preterm 64 (37.9)
Average difference in GA between 
pregnancies, in weeks (SD)c 8.25 (6.11)
Adherence
Mean PDC (SD) 0.79 (0.26)
Number of adherent members 112 (66.3)
Number of clinical comorbidities
0 16 (9.4)
1 64 (37.9)
2 52 (30.8)
≥ 3 37 (21.9)
Type of clinical comorbidity
Nutritional disorder or anemia 139 (51.3)
Depression or anxiety 57 (21.0)
Bacteriuria 38 (14.0)
STD or SUD 37 (13.7)
a All numbers presented as n (%) unless otherwise noted, b Term = delivery at > 37 weeks gestational age,  
Preterm = delivery at < 37 weeks gestational age, c n = 142 
CI – confidence interval, GA – gestational age, GYN – gynecology, MFM – maternal family medicine, MLP – mid-level practitioner,  
PA – prior authorization, PDC – proportion of days covered, OB – obstetrics, SD – standard deviation, STD – sexually transmitted disease, 
SUD – substance use disorder
TABLE 1: 
Descriptive Characteristics and Birth and  
Adherence Outcomes
Term Deliverya,b,c
P-Valued
Term N (%) Preterm N (%)
Race
Black 16 (53.3) 14 (46.7)
0.2734
Non-black 89 (64.0) 50 (36.0)
PDC categories
≥ 0.8 65 (58.0) 47 (42.0)
0.1240
< 0.8 40 (70.2) 17 (29.8)
Number of clinical comorbidities
0 c c
0.8715
1 42 (65.6) 22 (34.4)
2 31 (59.6) 21 (40.4)
≥ 3 23 (62.2) 14 (37.8)
Type of clinical comorbidity
Nutritional disorder or anemia 89 (64.0) 50 (36.0) 0.2734
Depression or anxiety 34 (59.6) 23 (40.4) 0.6352
Bacteriuria 24 (63.2) 14 (36.8) 0.8821
STD or SUD 22 (59.5) 15 (40.5) 0.7047
a Numbers presented as n (%), b Term = delivery at > 37 weeks gestational age, Preterm = delivery at < 37 weeks gestational age,  
c Data for category not presented to protect member privacy due to low numbers, d Chi-square Test
PDC – proportion of days covered, STD – sexually transmitted disease, SUD – substance use disorder 
 
TABLE 2: 
Birth Outcome Bivariate Analysis
  PDCa,b
P-Valuec
≥ 0.8 N (%) < 0.8 N (%)
Race
Black 16 (53.3) 14 (46.7)
0.0984
Non-black 96 (69.0) 43 (31.0)
Number of clinical comorbidities
0 b b
0.9261
1 41 (64.1) 23 (35.9)
2 34 (65.4) 18 (34.6)
≥ 3 26 (70.3) 11 (29.7)
Type of clinical comorbidity
Nutritional disorder or anemia 91 (65.5) 48 (34.5) 0.6339
Depression or anxiety 36 (63.2) 21 (36.8) 0.5413
Bacteriuria 24 (63.2) 14 (36.8) 0.6446
STD or SUD 25 (67.6) 12 (32.4) 0.8504
a Numbers presented as n (%), b Data for category not presented to protect member privacy due to low numbers, c Chi-square Test 
PDC – proportion of days covered, STD – sexually transmitted disease, SUD – substance use disorder 
TABLE 3: 
Medication Adherence Bivariate Analysis
Gestational age of prior 
pregnancy (weeks)
<28 (n=55) 28 to 31 (n=32) 32 to 36 (n=65) Total (n=152)
Prior pregnancy Study pregnancy Prior pregnancy Study pregnancy Prior pregnancy Study pregnancy Prior pregnancy Study pregnancy
Cost of medical care $14,561,202.15 $1,913,519.87 $4,349,034.78 $504,008.44 $1,230,657.35 $1,191,092.39 $20,140,894.28 $3,608,620.70
Cost of medication - $822,583.50 - $473,167.50 - $1,008,210.75 - $2,303,961.75
Total cost of care $14,561,202.15 $2,736,103.37 $4,349,034.78 $977,175.94 $1,230,657.35 $2,199,303.14 $20,140,894.28 $5,912,582.45
Difference in cost  
between pregnancies ($11,825,098.78) ($3,371,858.84) $968,645.79 ($14,228,311.83)
*Inflation rate of 1.39 for 2005 to 2015 dollars applied
TABLE 4: 
Cost Comparison Between Prior Pregnancy and Study Pregnancy by Gestational Age*
FIGURE 1: 
Study Enrollment
Members with PA 
request submitted for 
progesterone agent
N=418
Members eligible  
for study
N=190
Members who received progesterone for 
prevention of PTB enrolled in the study
N=169
Members meeting 
exclusion criteria:
MH was secondary payer  
n=85
Breaks in coverage  
n=69
Progesterone not indicated 
for prevention of PTB  
n=22
Current gestational week  
not provided on PA form  
n=25
Date of delivery unavailable  
n = 27
Member did not have paid 
medical or pharmacy claim 
for approved progesterone 
agent or the PA  
request was denied
n=21
FIGURE 2: 
Proportion of 
Adherent Members
Adherent
Non-Adherent
n=112 
(66.3%)
n=57 
(33.7%)
Adherence is defined as proportion 
of days covered ≥ 0.8
MH – MassHealth, PA – prior authorization, PTB – preterm birth © 2017 University of Massachusetts Medical School
